secwatch.observer — SEC 8-K summary
======================================

Issuer:     Akebia Therapeutics, Inc. (AKBA)
CIK:        0001517022
Form:       8-K
Filed at:   2023-06-08T23:59:59+00:00
Accession:  0001517022-23-000014
Event type: other
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.02, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Akebia shareholders elect three directors, approve 2023 stock plan at annual meeting
--------------------------------------------------------------------------------

- Class III directors Adrian Adams, Michael Rogers, LeAnne M. Zumwalt elected for three-year terms.
- 2023 Stock Incentive Plan approved: 61.2M for, 22.8M against, 508K abstentions.
- Non-binding advisory vote on executive compensation passed: 59.7M for, 24.2M against.
- Ernst & Young LLP ratified as auditor for FY2023: 116.5M for, 5.2M against.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1517022/000151702223000014/0001517022-23-000014-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1517022/000151702223000014/akba-20230606.htm
  HTML page:      https://secwatch.observer/filing/0001517022-23-000014

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer